Find a Parkview Health Clinical Trial
8 results found
Current Studies
Specific Study Aims: Study Aim 1: The primary aim of this study was to determine the technical success of ESD using the retraction device by determining completeness of the resection (�en-bloc vs incomplete). Study Aim 2: We aim to determine the safety of the device with regards to perforation and...
Primary: Progression-free survival (PFS) To determine the efficacy by progression free survival (using investigator assessment of scans according to RECIST v1.1) of oregovomab compared to placebo when administered with background chemotherapy (paclitaxel/carboplatin) to subjects with...
OBJECTIVES Primary Objective To assess the clinical activity (overall response rate) of tazemetostat in patients with recurrent or persistent endometrioid or clear cell ovarian carcinoma, and patients with recurrent or persistent endometrioid endometrial adenocarcinoma. Secondary Objectives To...
Primary Objective To examine if letrozole monotherapy/maintenance is non-inferior to IV paclitaxel/carboplatin and maintenance letrozole with respect to PFS in women with stage II-IV primary low-grade serous carcinoma of the ovary or peritoneum after primary surgical cytoreduction. Secondary...
Primary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) [Time Frame: Up to approximately 38 months] Overall Survival (OS) [Time Frame: Up to approximately 46 months] Secondary: Progression-Free Survival (PFS) Per Response Evaluation...
Primary Objective a To evaluate the RECIST v1.1 overall response rate (ORR) in subsets of patients with advanced rare cancers treated with ipilimumab plus nivolumab combination immunotherapy. b To evaluate the overall response rate (ORR, per criteria in Section 10.8) in patients with gestational...
To compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, with respect to progression-free survival (PFS) per RECIST 1.1 as assessed by the investigator Hypothesis (H1): pembrolizumab plus paclitaxel with or without bevacizumab is...